Epsilogen appoints Board member Peter Finan as Non-Executive Chairman

– UK, London –  Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, announced the appointment of current Non-Executive Director Dr. Peter Finan (Ph.D.)to the role of Non-Executive Chairman with immediate effect.

Concurrently, the company announced the appointment of Ashley Nagle as Chief Business Officer.

About Pete Finan

Pete Finan replaces Dave Chiswell as Non-Executive Chairman, who is stepping down for personal reasons after five years in the role. Pete has more than 30 years of experience in drug discovery within the biopharmaceutical industry and is a Partner at Epidarex Capital. During his career, Pete has also served as Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the UK and as Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts.

Pete Finan holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.

About Ashley Nagle

Ashley Nagle brings over 25 years of experience leading business and strategy development, licensing, and deal-making within the biopharmaceutical industry. Most recently, Ashley Nagle served as VP of Business Development at RemedyBio, a discovery and development precision immunotherapy company. During his career, he has worked with both small and large organizations, including Lonza Biologics, Almac Sciences, Fulcrum Pharma, OncoSynergy, NexGenix, and SeaGull Therapeutics, where he was CBO.

Ashley Nagle holds a BSc in Chemistry from University College Cork, an MSc in Analytical Chemistry and Environmental Sciences from the University of Aberdeen, and an MBA from the University of Lincoln.

About Epsilogen Ltd

Epsilongen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defense against certain parasites. This functionality makes it an ideal treatment for solid tumors due to its strong potency, enhanced tumor access, and long tissue half-life.

Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic, and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently completed large-scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in Platinum-Resistant varian Cancer Patients later this year. The company is also developing a proprietary IgEG antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.

Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures, and Schroders Capital amongst others.

SOURCE: https://epsilogen.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.